Protecting Your Pathology: Cybersecurity for Digital Workflows
Digital pathology opens up new cybersecurity risks for labs—but simple steps can mitigate those risks and increase digital resilience
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
Digital pathology opens up new cybersecurity risks for labs—but simple steps can mitigate those risks and increase digital resilience
New study shows that ctDNA liquid biopsy testing after stage II colon cancer may determine whether chemotherapy is required.
A new study suggests that this is a viable idea, particularly in the context of diabetes screening in a Latinx community.
Inhalers and sensors that offer digital monitoring are beginning to gain FDA approval, and could solve usage issues of traditional products.
Revised guidelines from the American Urological Association support limited use of the tests for certain prostate cancer patients.
The move comes shortly after the FDA said it was going to decline some pre-submission requests to focus on pandemic-related diagnostics.
New research led by the American Cancer Society shows decreases in cervical and breast cancer screening during the pandemic.
Newly proposed legislation would establish a risk-based regulatory system for LDT regulation, though not everyone is happy with it.
Despite the emergence and rise of new Omicron variants, COVID-19 testing has declined as much as 90 percent, according to some reports.
Recent developments suggest that we are on the precipice of a new age offering expanded options for Alzheimer’s diagnosis.
Recent study suggests those being treated for acute conditions are likelier to schedule follow-up appointments after telehealth visits.